CLINICAL_TRIALS ClinicalTrials.gov record update

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02646748
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:43.958712+00:00
Published At: 2022-03-31T00:00:00+00:00
Record Updated At: 2022-03-31
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Colorectal Cancer (CRC)", "Endometrial Cancer", "Melanoma", "Head and Neck Cancer", "Lung Cancer", "MMR-deficient Tumors", "Breast Cancer", "Pancreatic Cancer", "Renal Cell Carcinoma (RCC)", "Solid Tumors", "UC (Urothelial Cancer)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-03-31"
protocolSection.identificationModule.nctId: "NCT02646748"
protocolSection.identificationModule.officialTitle: "A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.